Trials / Terminated
TerminatedNCT04248153
Optimal Timing of BR55 CEUS of the Ovaries
An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Bracco Diagnostics, Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BR55 | BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg |
Timeline
- Start date
- 2019-10-14
- Primary completion
- 2020-02-19
- Completion
- 2021-07-31
- First posted
- 2020-01-30
- Last updated
- 2024-08-23
- Results posted
- 2024-08-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04248153. Inclusion in this directory is not an endorsement.